founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
Company profile
Ticker
DXCM
Exchange
Website
CEO
Kevin Sayer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
SweetSpot Diabetes Care, Inc. • TypeZero Technologies, Inc. • DexCapital, LLC • The Glucose Program, LLC • Nintamed Handels GmbH • DexCom Canada, Co. • DexCom International Ltd. • DexCom Deutschland GmbH • DexCom (Malaysia) Sdn. Bhd. • DexCom Philippines Inc. ...
IRS number
330857544
DXCM stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
25 Apr 24
8-K
Dexcom Reports First Quarter 2024 Financial Results
25 Apr 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
8-K
Entry into a Material Definitive Agreement
15 Feb 24
10-K
2023 FY
Annual report
8 Feb 24
8-K
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
8 Feb 24
8-K
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook
8 Jan 24
8-K
Other Events
2 Nov 23
10-Q
2023 Q3
Quarterly report
26 Oct 23
Transcripts
DXCM
Earnings call transcript
2024 Q1
25 Apr 24
DXCM
Earnings call transcript
2023 Q4
8 Feb 24
DXCM
Earnings call transcript
2023 Q3
26 Oct 23
DXCM
Earnings call transcript
2023 Q2
27 Jul 23
DXCM
Earnings call transcript
2023 Q1
27 Apr 23
DXCM
Earnings call transcript
2022 Q4
9 Feb 23
DXCM
Earnings call transcript
2022 Q3
27 Oct 22
DXCM
Earnings call transcript
2022 Q2
29 Jul 22
DXCM
Earnings call transcript
2022 Q1
29 Apr 22
DXCM
Earnings call transcript
2021 Q4
11 Feb 22
Latest ownership filings
144
Notice of proposed sale of securities
23 Apr 24
4
Matthew Vincent Dolan
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
KEVIN R SAYER
10 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Michael Jon Brown
29 Mar 24
144
Notice of proposed sale of securities
28 Mar 24
4
Sadie Stern
26 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 644.80 mm | 644.80 mm | 644.80 mm | 644.80 mm | 644.80 mm | 644.80 mm |
Cash burn (monthly) | 183.73 mm | 4.53 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 1.26 bn | 31.12 mm | n/a | n/a | n/a | n/a |
Cash remaining | -618.86 mm | 613.68 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | -3.4 | 135.6 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
91.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 878 |
Opened positions | 116 |
Closed positions | 154 |
Increased positions | 331 |
Reduced positions | 321 |
13F shares | Current |
---|---|
Total value | 33.77 tn |
Total shares | 362.58 mm |
Total puts | 5.16 mm |
Total calls | 4.42 mm |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 44.19 mm | $4.12 tn |
BLK Blackrock | 32.74 mm | $3.05 tn |
Baillie Gifford & Co | 16.68 mm | $1.56 tn |
STT State Street | 16.04 mm | $1.50 tn |
Sands Capital Management | 13.66 mm | $1.27 tn |
Capital Research Global Investors | 12.60 mm | $1.18 tn |
FMR | 9.02 mm | $841.30 bn |
Geode Capital Management | 8.73 mm | $812.73 bn |
Nuveen Asset Management | 7.75 mm | $723.08 bn |
IVZ Invesco | 6.50 mm | $606.78 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Matthew Vincent Dolan | Common Stock | Sell | Dispose S | No | Yes | 137.81 | 1,990 | 274.24 k | 42,377 |
8 Apr 24 | Sayer Kevin R | Common Stock | Sell | Dispose S | No | Yes | 138.7079 | 22,361 | 3.10 mm | 283,893 |
8 Apr 24 | Sayer Kevin R | Common Stock | Sell | Dispose S | No | Yes | 137.9616 | 27,272 | 3.76 mm | 306,254 |
28 Mar 24 | Micheal Jon Brown | Common Stock | Sell | Dispose S | No | Yes | 140.73 | 100 | 14.07 k | 68,682 |
28 Mar 24 | Micheal Jon Brown | Common Stock | Sell | Dispose S | No | Yes | 140.0156 | 2,524 | 353.40 k | 68,782 |
25 Mar 24 | Sadie Stern | Common Stock | Sell | Dispose S | No | Yes | 140 | 4,137 | 579.18 k | 76,304 |
15 Mar 24 | Matthew Vincent Dolan | Common Stock | Sell | Dispose S | No | Yes | 131.3912 | 1,003 | 131.79 k | 44,367 |
15 Mar 24 | Matthew Vincent Dolan | Common Stock | Sell | Dispose S | No | Yes | 130.7704 | 1,314 | 171.83 k | 45,370 |
15 Mar 24 | Matthew Vincent Dolan | Common Stock | Sell | Dispose S | No | Yes | 129.1842 | 1,886 | 243.64 k | 46,684 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
25 Apr 24
Peering Into DexCom's Recent Short Interest
25 Apr 24
DexCom Q1 2024 Adj EPS $0.32 Beats $0.27 Estimate, Sales $921.000M Beat $909.238M Estimate
25 Apr 24
$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today
17 Apr 24
The Analyst Verdict: DexCom In The Eyes Of 4 Experts
10 Apr 24
Press releases
Dexcom Reports First Quarter 2024 Financial Results
25 Apr 24
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
2 Apr 24
Dexcom Announces Upcoming Conference Presentation
27 Feb 24
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
8 Feb 24